NovoCure Limited Ordinary Shares (NVCR)

Price$17.16

Value ScoreD

Growth ScoreC

Momentum ScoreB

Favorite Metrics

Price vs S&P 500 (26W)26.03%

Price vs S&P 500 (4W)-4.07%

VGM Score48.70

Market Capitalization$1.99B

All Metrics

Book Value / Share (Quarterly)$2.86

P/TBV (Annual)3.02x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)6.81%

Cash Flow / Share (Quarterly)$-0.23

Price vs S&P 500 (YTD)24.56%

Gross Margin (TTM)75.39%

Net Profit Margin (TTM)-25.66%

EPS (TTM)$-1.53

10-Day Avg Trading Volume1.59M

EPS Excl Extra (TTM)$-1.53

Revenue Growth (5Y)5.80%

EPS (Annual)$-1.22

ROI (Annual)-25.44%

Gross Margin (Annual)74.54%

Net Profit Margin (5Y Avg)-23.48%

Cash / Share (Quarterly)$3.73

Revenue Growth QoQ (YoY)12.30%

ROA (Last FY)-16.94%

Revenue Growth TTM (YoY)8.48%

EBITD / Share (TTM)$-1.48

ROE (5Y Avg)-35.83%

Operating Margin (TTM)-27.02%

Cash Flow / Share (Annual)$-0.67

P/B Ratio6.01x

P/B Ratio (Quarterly)3.75x

Net Income / Employee (Annual)$-84,900

EV / Revenue (TTM)4.06x

Net Interest Coverage (TTM)-15.06x

ROA (TTM)-13.50%

EV / EBITDA (TTM)1822.11x

EPS Incl Extra (Annual)$-1.22

Current Ratio (Annual)2.90x

Quick Ratio (Quarterly)2.70x

3-Month Avg Trading Volume1.89M

52-Week Price Return4.32%

Revenue / Employee (TTM)$420,200

Tangible BV / Share (Quarterly)$3.69

P/S Ratio (Annual)3.03x

Asset Turnover (Annual)0.81x

52-Week High$19.25

Operating Margin (5Y Avg)-24.46%

EPS Excl Extra (Annual)$-1.22

CapEx CAGR (5Y)12.22%

Tangible BV CAGR (5Y)31.18%

26-Week Price Return33.96%

Quick Ratio (Annual)2.57x

13-Week Price Return20.59%

Total Debt / Equity (Annual)0.57x

Current Ratio (Quarterly)2.90x

Enterprise Value$2.10B

Revenue / Share Growth (5Y)5.31%

Asset Turnover (TTM)0.52x

Book Value / Share Growth (5Y)-8.26%

Revenue / Employee (Annual)$408,300

Inventory Turnover (Annual)4.38x

Pretax Margin (Annual)-20.79%

Cash / Share (Annual)$3.98

3-Month Return Std Dev82.15%

Gross Margin (5Y Avg)76.78%

Net Income / Employee (TTM)$-107,800

ROE (Last FY)-40.01%

Net Interest Coverage (Annual)-36.68x

EPS Basic Excl Extra (Annual)$-1.22

P/FCF (TTM)133.22x

Receivables Turnover (TTM)7.59x

Total Debt / Equity (Quarterly)0.59x

EPS Incl Extra (TTM)$-1.53

Receivables Turnover (Annual)8.01x

ROI (TTM)-18.47%

P/S Ratio (TTM)2.95x

Pretax Margin (5Y Avg)-21.01%

Revenue / Share (Annual)$5.88

Tangible BV / Share (Annual)$4.20

Price vs S&P 500 (52W)-20.05%

Year-to-Date Return32.71%

5-Day Price Return3.62%

EPS Normalized (Annual)$-1.22

ROA (5Y Avg)-12.30%

Net Profit Margin (Annual)-20.79%

Month-to-Date Return0.70%

Cash Flow / Share (TTM)$-1.76

EBITD / Share (Annual)$-1.25

Operating Margin (Annual)-23.47%

LT Debt / Equity (Annual)0.57x

ROI (5Y Avg)-15.89%

LT Debt / Equity (Quarterly)0.59x

EPS Basic Excl Extra (TTM)$-1.53

P/TBV (Quarterly)3.38x

P/B Ratio (Annual)4.25x

Inventory Turnover (TTM)4.00x

Pretax Margin (TTM)-25.98%

Book Value / Share (Annual)$3.03

Price vs S&P 500 (13W)12.34%

Beta0.98x

P/FCF (Annual)210.76x

Revenue / Share (TTM)$5.91

ROE (TTM)-39.38%

52-Week Low$9.82

vGradeD

gGradeC

mGradeB

vgmGradeC

Show chart for

Earnings Surprise History

Q1 26-0.62est. -0.52

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.08

Industry Peers — Surgical & Medical Instruments(138)

Symbol	Value Score	Growth Score	Momentum Score	Price
NVCRNovoCure Limited Ordinary Shares	D	C	B	$17.16
SYKStryker Corporation	C	C	C	$305.66
MMM3M Company	C	F	C	$153.76
BSXBoston Scientific Corp.	C	B	D	$48.55
MDLNMedline Inc. Class A common stock	C	D	D	$33.61
BDXBecton, Dickinson and Co.	B	C	C	$151.16
RMDResMed Inc.	C	B	C	$196.04
DXCMDexCom, Inc.	C	B	C	$72.86
WSTWest Pharmaceutical Services, Inc.	D	C	B	$314.50
SOLVSolventum Corporation	C	D	B	$81.01
PENPenumbra, Inc.	F	C	B	$320.53

About

NovoCure Ltd is an oncology company that develops and commercializes Tumor Treating Fields (TTFields) devices, a proprietary technology platform for treating solid tumors. The company's approved products, Optune Gio and Optune Lua, treat glioblastoma, non-small cell lung cancer, and pancreatic cancer, while its pipeline includes Trident, Lunar-2, Panova-3, and Metis candidates. With headquarters in the United States, NovoCure generates the majority of its revenue domestically, with additional sales from Germany, Japan, and other international markets.